Empagliflozin (Jardiance®). HTA ID: 22068
Empagliflozin (Jardiance®) is indicated in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40%.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 02/11/2022 |
| Rapid review completed | 02/12/2022 |
| Rapid Review outcome | A full HTA is not recommended. The NCPE recommends that empagliflozin for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40% be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.